Due to that CD80/CD86-CTLA4 axis were involved in the crosstalk between myeloid cells and T cells, and that the application of CTLA4 blockade has been widespread in tumor immunotherapy, we investigated the value of targeting CD80/CD86-CTLA4 axis under inflammatory conditions. The gene discussed is CTLA4; the disease is neoplasm.